EUVIMEDEUVIMED entdecken
Open Access

Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans

Leila Hashemi, Andriana Marijic Buljubasic, Matthew J Budoff, Laurel A Copeland, Nicholas J Jackson, Guneet K Jasuja, Jeffery Gornbein, Karen Reue

JAMA Network Open · 02.07.2024 · 7 (7) · e2419696

DOI: 10.1001/jamanetworkopen.2024.19696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 02.07.2024. Verfasst von Leila Hashemi und 7 weiteren Autor:innen. Beteiligte Einrichtung: VA Greater Los Angeles Health Care System, Department of General Internal Medicine, David Geffen School of Medicine, Los Angeles, California. Hauptthemen laut MEDLINE: Metabolic Syndrome, Transgender Persons, Veterans, Testosterone. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Gender-affirming hormone treatment (GAHT) is a common therapy for transgender individuals to reduce gender dysphoria and improve quality of life. Clarifying the long-term effects of GAHT remains a priority in transgender health research.

Objective

To explore whether sex hormones (estradiol and testosterone) are associated with the development of metabolic syndrome in transgender veterans compared with cisgender veterans. Design, Setting, and Participants This retrospective, longitudinal cohort study used International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes for gender dysphoria from the Veterans Health Administration national database to identify transfeminine and transmasculine veterans receiving documented feminizing (estradiol) or masculinizing (testosterone) treatment from January 1, 2006, to December 31, 2019, and for whom the GAHT initiation date and metabolic syndrome component–related data were available. Transgender veterans were matched to cisgender referents. Exposure Gender-affirming hormone treatment. Main Outcomes and Measures Metabolic syndrome z-scores were calculated based on body mass index, systolic blood pressure, and levels of high-density lipoprotein cholesterol, triglycerides, and blood glucose. Changes in mean z-scores were compared among the transgender and cisgender groups before and after the index date (corresponding to GAHT initiation) using a repeated-measures analysis of variance model.

Results

The cohort included 1290 participants: 645 transgender (494 [38.3%] transfeminine, 151 [11.7%] transmasculine) and 645 cisgender (280 [21.7%] female, 365 [28.3%] male). Mean (SD) age at the index date was 41.3 (13.2) years. Metabolic syndrome z-scores changed significantly over time and differed significantly across groups. Overall, transmasculine veterans had the greatest percentage increase in mean (SEM) z-scores after vs before the index date (298.0% [57.0%]; P < .001), followed by cisgender females (108.3% [27.5%]; P < .001), cisgender males (49.3% [27.5%]; P = .02), and transfeminine persons (3.0% [10.7%]; P = .77). Conclusions and Relevance In this cohort study, in both cisgender and transgender veterans, estradiol was associated with reduced metabolic syndrome risk, whereas testosterone was associated with increased risk. However, transmasculine individuals had the greatest risk and transfeminine individuals had the lowest risk of metabolic syndrome associated with these hormones. This is relevant for the management of metabolic syndrome risk factors in cisgender and transgender individuals and to potentially predict the risk of atherosclerotic cardiovascular disease, type 2 diabetes, systolic hypertension, insulin resistance, and nonalcoholic fatty liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeTransgender PersonsVeteransTestosteroneGender DysphoriaHumansMaleFemaleRetrospective StudiesAdultLongitudinal StudiesMiddle AgedEstradiolUnited States

Substanzen

TestosteroneEstradiol

Autor:innen und Institutionen

  • VA Greater Los Angeles Health Care System, Department of General Internal Medicine, David Geffen School of Medicine, Los Angeles, California.
  • Yale School of Public Health, New Haven, Connecticut.
  • Department of Medicine, Lundquist Institute at Harbor-UCLA, Torrance, California.
  • VA Central Western Massachusetts Health Care System, Leeds.
  • Statistics Core, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
  • Center for Healthcare Organization & Implementation Research, US Department of Veterans Affairs, VA Bedford Health Care System, Bedford, Massachusetts.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Hashemi, L., Marijic Buljubasic, A., Budoff, M. J., Copeland, L. A., Jackson, N. J., Jasuja, G. K., Gornbein, J., & Reue, K. (2024). Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans. JAMA Network Open, 7(7), e2419696. https://doi.org/10.1001/jamanetworkopen.2024.19696

Vancouver

Hashemi L, Marijic Buljubasic A, Budoff MJ, Copeland LA, Jackson NJ, Jasuja GK, et al. Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans. JAMA Network Open. 2024;7(7):e2419696. doi:10.1001/jamanetworkopen.2024.19696

BibTeX
@article{Hashemi2024,
  author = {Hashemi, Leila and Marijic Buljubasic, Andriana and Budoff, Matthew J and Copeland, Laurel A and Jackson, Nicholas J and Jasuja, Guneet K and Gornbein, Jeffery and Reue, Karen},
  title = {Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {7},
  pages = {e2419696},
  doi = {10.1001/jamanetworkopen.2024.19696}
}
Kostenlos starten →